Design, DNA binding and kinetic studies, antibacterial and cytotoxic activities of stable dithiophenolato titanium(IV)-chitosan Nanocomposite
Publication date: Available online 21 May 2019Source: Journal of Molecular LiquidsAuthor(s): Nadia Z. Shaban, Salah A. Yehia, Kamel R. Shoueir, Samar R. Saleh, Doaa Awad, Shaban Y. ShabanAbstractHighly thermal stable dithiophenolato Ti(IV)-chitosan nanocomposite (DBT-CS) was formed from dithiophenolato Ti(IV)-complex (DBT) and chitosan (CS) nanoparticles. As DNA-drugs binding is the key reaction step responsible for the anticancer activity, in vitro DNA binding studies to DBT and DBT-CS were investigated and showed a strong interaction to DNA helix via groove binding. Kinetic stability, affinity and association constants of compounds-DNA were studied for the first time using a stopped-flow technique and showed that the formulation of nanostructure DBT-CS does not only improve the rate of reaction through coordination affinity but also change the binding mechanism. Additionally, the antibacterial investigation showed that DBT and DBT-CS exhibited good antibacterial activity against both Gram-positive and Gram-negative bacteria. They also show high cytotoxicity against HepG2 human liver cancer cell. Although DBT-DNA complex is kinetically more stable than that of DBT-CS, the latter showed better antibacterial and cytotoxic activities which in agreement with the binding constants.Graphical abstract
Using 3D-printed models based on chest CT scans allows clinicians to personalize...Read more on AuntMinnie.comRelated Reading: AR, 3D printing enhance planning for complex heart surgery Radiologists rally in support of medical 3D printing AR, 3D printing aid presurgical planning for kidney cancer 3D printing reduces liver transplant costs, surgery time 3D printing boosts efficiency of rib fracture repair
Conclusions: Due to the complexity of the behavior and biology of cells, scientists' primary focus should be on detection and elimination of sources of inflammation. Antiparasitic medications, and also antiviral, antibiotic, and antifungal medications should be thought of as underrecognized, underappreciated, and forgotten medications that can be part of cancer therapy. The information offered in this review suggests scientists should think of cancer not only as a metabolic disease but also as a metabolic parasite and should consider using antiparasitic medications under a new understanding of the role of inflammation, inf...
Conclusions: While case reports cannot be considered as proof of efficacy, these cases added to others of patients treated with the same method would suggest that this is a viable option for those patients whose disease cannot be treated successfully with other modalities. PMID: 31202206 [PubMed - in process]
Publication date: Available online 15 June 2019Source: Seminars in Cancer BiologyAuthor(s): Michael Timaner, Kelvin Tsai, Yuval ShakedAbstractMesenchymal stem cells (MSCs) are multipotent stem cells derived from the mesoderm that give rise to several mesenchymal lineages, including osteoblasts, adipocytes, chondrocytes and myocytes. Their potent ability to home to tumors coupled with their differentiation potential and immunosuppressive function positions MSCs as key regulators of tumor fate. Here we review the existing knowledge on the involvement of MSCs in multiple tumor-promoting processes, including angiogenesis, epit...
Publication date: August 2019Source: Cancer Epidemiology, Volume 61Author(s): Ryan Wendt, Yubo Gao, Benjamin J. MillerAbstractBackgroundThere is an undefined relationship between access to regional referral centers and whether the eventual oncologic outcomes are influenced by distance, travel time, or residence in a rural community.MethodsWe used the Surveillance, Epidemiology and End Results (SEER) Program Database to capture all cases of high-grade osteosarcoma from 1990 to 2014 in Iowa, Utah, and New Mexico. Using univariate, Kaplan Meier survival analysis, and multivariate Cox proportional hazards modeling we analyzed ...
ConclusionsCNS-RF is a relevant measure of prognosis in patients who have already achieved a period of remission. Providing an updated estimation of prognosis in the years following diagnosis may improve the survivors’ quality of life and access to credit or insurance.
You are leaving AARP.org and going to the website of our trusted provider. ... The provider ’s terms, conditions and policies apply. ... Please return to AARP.org to learn more about other benefits.